A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Lunai Bioworks Inc.
LNAI
$27M
Mkt Cap
$2.43
-6.70%
Our Business Lunai Bioworks Inc. operates through three subsidiaries, Renovaro Biosciences, Renovaro Cube and BioSymetrics. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V., which were acquired on February 13, 2024. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. Renovaro Biosciences Overview Renovaro Biosciences is a biotechnology company intending, if the necessary funding is obtained, to develop advanced allogeneic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers. As a result of our acquisition of GEDi Cube Intl on February 13, 2024, we have shifted the Company’s primary focus and resources to the development of the GEDi Cube Intl technologies.
| Metric | TTM | FY2023 | FY2022 | FY2016 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 0 | - |
| Net Income | -128M | -40M | -113M | -1.7M | -2.4M | -2.1M |
| EPS | $-0.74 | $-3.55 | $-10.80 | $-1.80 | $-3.20 | $-4.00 |
| Free Cash Flow | 0 | -12M | -16M | -1.5M | -2.0M | -2.1M |
| ROIC | -1069.4% | -65.3% | -90.9% | - | -66.2% | -305.0% |
| Gross Margin | - | - | - | 0.0% | 0.0% | 0.0% |
| Debt/Equity | 0.00 | 0.13 | 0.03 | - | 0.01 | -0.30 |
| Dividends/Share | $0.00 | - | - | $0.00 | $0.00 | $0.00 |
| Operating Income | -133M | -39M | -116M | -2.1M | -2.4M | -1.7M |
| Operating Margin | 0.0% | - | - | 0.0% | 0.0% | 0.0% |
| ROE | 0.0% | -66.6% | -91.7% | - | -263.7% | - |
| Shares Outstanding | 36M | 11M | 11M | 1M | 1M | 1M |
| Metric | 2013 | 2014 | 2016 | ||||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0 | N/A | 0 | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | 804K | 8.4M | 4.2M | 624K |
| SG&A | 30K | 1.2M | 1.6M | 1.2M | 14M | 15M | 9.6M |
| EBIT | -30K | -1.7M | -2.4M | -2.1M | -116M | -39M | -133M |
| Op. Margin | N/A | 0.0% | 0.0% | 0.0% | N/A | N/A | 0.0% |
| Net Income | -30K | -2.1M | -2.4M | -1.7M | -113M | -40M | -128M |
| Net Margin | N/A | 0.0% | 0.0% | 0.0% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 93M | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -5.3% | N/M | -66.2% | N/A | -90.9% | -65.3% | N/M |
| ROE | 267.2% | N/A | -263.7% | N/A | -91.7% | -66.6% | 0.0% |
| ROA | -220.9% | -476.7% | -83.3% | N/A | -82.7% | -55.5% | -1301.0% |
| Cash Flow | |||||||
| Op. Cash Flow | -25K | -2.1M | -2.0M | -1.5M | -16M | -12M | -5.3M |
| Free Cash Flow | -25K | -2.1M | -2.0M | -1.5M | -16M | -12M | 0 |
| Owner Earnings | -25K | -2.2M | -2.1M | -1.5M | -21M | -15M | -7.6M |
| CapEx | 0 | 0 | 0 | 0 | 5K | 30K | 0 |
| Maint. CapEx | 0 | 38K | 19K | 27K | 124K | 113K | 96K |
| Growth CapEx | N/A | N/A | N/A | N/A | 0 | 0 | 0 |
| D&A | 0 | 38K | 19K | 27K | 124K | 113K | 96K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | 0 | 5.2M | 3.5M | 2.3M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | 457K | 484K | -3.0M | -23K | -6.8M | 4.0M | -3.0M |
| Cash & Equiv. | 4K | 19K | 3.0M | 23K | 9.2M | 1.9M | 3.2M |
| Long-Term Debt | N/A | 728K | 100K | 103K | 1.2M | 1.2M | 120K |
| Debt/Equity | -33.72 | -0.30 | 0.01 | N/A | 0.03 | 0.13 | 0.00 |
| Interest Coverage | N/A | -2.7 | -28.7 | -897.2 | -311.3 | -66.4 | -66.4 |
| Equity | -14K | -1.7M | 3.5M | N/A | 73M | 47M | -9.6M |
| Total Assets | 14K | 450K | 5.2M | N/A | 85M | 58M | 9.9M |
| Total Liabilities | 27K | 2.1M | 1.8M | 1.5M | 12M | 12M | 19M |
| Intangibles | N/A | 232K | 186K | 136K | 44K | 40K | 119K |
| Retained Earnings | N/A | -20M | -22M | -26M | -204M | -244M | -512M |
| Working Capital | -14K | -2.0M | 3.3M | -776K | 3.1M | -8.5M | -16M |
| Current Assets | 14K | 141K | 5.0M | 732K | 9.6M | 2.6M | 3.7M |
| Current Liabilities | 27K | 2.1M | 1.8M | 1.5M | 6.5M | 11M | 19M |
| Per Share Data | |||||||
| EPS | 0.00 | -4.00 | -3.20 | -1.80 | -10.80 | -3.55 | -0.74 |
| Owner EPS | N/A | -4.04 | -2.77 | -1.56 | -2.01 | -1.38 | -0.21 |
| Book Value | N/A | -3.14 | 4.70 | N/A | 6.91 | 4.16 | -0.27 |
| Cash Flow/Share | N/A | -3.97 | -2.75 | -1.53 | -1.50 | -1.05 | -3.58 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 | N/A | N/A | 0.00 |
| Shares Out. | N/A | 0.5M | 0.7M | 1.0M | 10.5M | 11.2M | 35.8M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -3.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 0 | 87M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.43 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.43 |
Lunai Bioworks Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Lunai Bioworks Inc. (LNAI) has a 5-year average return on invested capital (ROIC) of -74.1%. This is below average and may indicate limited pricing power.
Lunai Bioworks Inc. (LNAI) has a market capitalization of $87M. It is classified as a small-cap stock.
Lunai Bioworks Inc. (LNAI) does not currently pay a regular dividend.
Lunai Bioworks Inc. (LNAI) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lunai Bioworks Inc. (LNAI) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Lunai Bioworks Inc. (LNAI) reported earnings per share (EPS) of $-3.55 in its most recent fiscal year.
Lunai Bioworks Inc. (LNAI) has a return on equity (ROE) of -66.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Lunai Bioworks Inc. (LNAI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lunai Bioworks Inc. (LNAI) has a book value per share of $4.16, based on its most recent annual SEC filing.